Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Durán R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M; International Liver Disease Genetics Consortium (ILDGC).

Sci Rep. 2019 Feb 5;9(1):1439. doi: 10.1038/s41598-018-35736-2.

2.

Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease.

Tosetti G, Primignani M, La Mura V, D'Ambrosio R, Degasperi E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P.

Dig Liver Dis. 2019 Jan 11. pii: S1590-8658(19)30006-4. doi: 10.1016/j.dld.2018.12.025. [Epub ahead of print]

PMID:
30691777
3.

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.

Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P.

Clin Gastroenterol Hepatol. 2018 Oct 26. pii: S1542-3565(18)31202-3. doi: 10.1016/j.cgh.2018.10.038. [Epub ahead of print]

PMID:
30613002
4.

Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.

Gendia M, Lampertico P, Alfieri CM, D'Ambrosio R, Gandolfo MT, Campise MR, Fabrizi F, Messa P.

Transpl Int. 2018 Dec 23. doi: 10.1111/tri.13393. [Epub ahead of print]

PMID:
30580473
5.

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.

D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group.

J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23.

PMID:
30472321
6.

Nonalcoholic fatty liver disease: is the IFNL4 rs368234815 variant protective from liver damage?

Galmozzi E, D'Ambrosio R.

Hepatobiliary Surg Nutr. 2018 Jun;7(3):209-211. doi: 10.21037/hbsn.2018.03.06. No abstract available.

7.

Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage.

Colucci G, D'Ambrosio R, Galmozzi E, Maggioni M, De Nicola S, Aghemo A, Colombo M.

Viral Immunol. 2018 Jun;31(5):358-361. doi: 10.1089/vim.2017.0190. Epub 2018 Apr 17.

PMID:
29664712
8.

Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F; BOSTIC Study Group.

J Viral Hepat. 2018 Aug;25(8):920-929. doi: 10.1111/jvh.12891. Epub 2018 Apr 17. Review.

PMID:
29532619
9.

12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.

Degasperi E, Aghemo A, Paolucci S, D'Ambrosio R, Borghi M, Perbellini R, Novazzi F, De Nicola S, Lunghi G, Baldanti F, Lampertico P.

Dig Liver Dis. 2018 Jul;50(7):703-706. doi: 10.1016/j.dld.2018.02.003. Epub 2018 Feb 12.

PMID:
29499903
10.

Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.

D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P.

Liver Int. 2018 Aug;38(8):1459-1467. doi: 10.1111/liv.13707. Epub 2018 Mar 12.

PMID:
29377616
11.

Methodological standards and interpretation of video-electroencephalography in adult control rodents. A TASK1-WG1 report of the AES/ILAE Translational Task Force of the ILAE.

Kadam SD, D'Ambrosio R, Duveau V, Roucard C, Garcia-Cairasco N, Ikeda A, de Curtis M, Galanopoulou AS, Kelly KM.

Epilepsia. 2017 Nov;58 Suppl 4:10-27. doi: 10.1111/epi.13903.

12.

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.

Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, De Franceschi L, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE).

Am J Hematol. 2017 Dec;92(12):1349-1355. doi: 10.1002/ajh.24911. Epub 2017 Oct 19.

13.

Zfp423/ZNF423 regulates cell cycle progression, the mode of cell division and the DNA-damage response in Purkinje neuron progenitors.

Casoni F, Croci L, Bosone C, D'Ambrosio R, Badaloni A, Gaudesi D, Barili V, Sarna JR, Tessarollo L, Cremona O, Hawkes R, Warming S, Consalez GG.

Development. 2017 Oct 15;144(20):3686-3697. doi: 10.1242/dev.155077. Epub 2017 Sep 11.

14.

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals.

D'Ambrosio R, Lampertico P.

Aliment Pharmacol Ther. 2017 Sep;46(6):628-629. doi: 10.1111/apt.14221. No abstract available.

PMID:
28805329
15.

Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature.

D'Ambrosio R, Maggioni M, Donato MF, Lampertico P, Cappellini MD, Graziadei G.

Hemoglobin. 2017 Mar;41(2):131-133. doi: 10.1080/03630269.2017.1341420. Review.

PMID:
28696845
16.

Direct-acting antivirals: the endgame for hepatitis C?

D'Ambrosio R, Degasperi E, Colombo M, Aghemo A.

Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15. Review.

PMID:
28419938
17.

Antiepileptic action of c-Jun N-terminal kinase (JNK) inhibition in an animal model of temporal lobe epilepsy.

Tai TY, Warner LN, Jones TD, Jung S, Concepcion FA, Skyrud DW, Fender J, Liu Y, Williams AD, Neumaier JF, D'Ambrosio R, Poolos NP.

Neuroscience. 2017 May 4;349:35-47. doi: 10.1016/j.neuroscience.2017.02.024. Epub 2017 Feb 22.

18.

Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis.

Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M.

Liver Int. 2017 Sep;37(9):1295-1303. doi: 10.1111/liv.13374. Epub 2017 Feb 23.

PMID:
28129465
19.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
20.

Chronic cholestasis in a patient with sickle-cell anemia: Histological findings.

D'Ambrosio R, Maggioni M, Graziadei G.

Dig Liver Dis. 2016 Nov;48(11):1402. doi: 10.1016/j.dld.2016.08.130. Epub 2016 Sep 8. No abstract available.

PMID:
27666963
21.

HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.

Degasperi E, De Nicola S, Rumi M, D'Ambrosio R.

J Hepatol. 2016 Nov;65(5):1058-1059. doi: 10.1016/j.jhep.2016.06.031. Epub 2016 Jul 25. No abstract available.

PMID:
27460835
22.

Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.

D'Ambrosio R, Aghemo A, Rossetti V, Carrinola R, Colombo M.

Liver Int. 2016 Nov;36(11):1585-1589. doi: 10.1111/liv.13203. Epub 2016 Aug 21. Review.

PMID:
27429162
23.

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M.

PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016.

24.

Estimation of optical properties of neuroendocrine pancreas tumor with double-integrating-sphere system and inverse Monte Carlo model.

Saccomandi P, Larocca ES, Rendina V, Schena E, D'Ambrosio R, Crescenzi A, Di Matteo FM, Silvestri S.

Lasers Med Sci. 2016 Aug;31(6):1041-50. doi: 10.1007/s10103-016-1948-1. Epub 2016 May 4.

PMID:
27147075
25.

Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection.

Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D'Ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1331-6. doi: 10.1016/j.cgh.2016.03.035. Epub 2016 Apr 1.

PMID:
27046484
26.

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group.

Dig Liver Dis. 2016 Jun;48(6):650-5. doi: 10.1016/j.dld.2016.02.004. Epub 2016 Feb 21.

PMID:
27012446
27.

Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?

D'Ambrosio R, Colombo M.

Liver Int. 2016 Jun;36(6):783-90. doi: 10.1111/liv.13106. Epub 2016 Mar 24. Review.

PMID:
26936383
28.

Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?

Galmozzi E, D'Ambrosio R.

Hepatology. 2016 Jul;64(1):322-3. doi: 10.1002/hep.28421. Epub 2016 Feb 22. No abstract available.

PMID:
26703937
29.

Modeling Post-Traumatic Epilepsy for Therapy Development.

Curia G, Eastman CL, Miller JW, D’Ambrosio R.

In: Laskowitz D, Grant G, editors. Translational Research in Traumatic Brain Injury. Boca Raton (FL): CRC Press/Taylor and Francis Group; 2016. Chapter 10.

30.

Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.

Daou B, Deprince M, D'Ambrosio R, Tjoumakaris S, Rosenwasser RH, Ackerman DJ, Bell R, Tzeng DL, Ghobrial M, Fernandez A, Shah Q, Gzesh DJ, Murphy D, Castaldo JE, Mathiesen C, Pineda MC, Jabbour P.

Clin Neurol Neurosurg. 2015 Dec;139:264-8. doi: 10.1016/j.clineuro.2015.10.010. Epub 2015 Oct 21.

PMID:
26539671
31.

Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.

Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, Abrignani S, Neddermann P, De Francesco R.

PLoS One. 2015 Sep 25;10(9):e0138546. doi: 10.1371/journal.pone.0138546. eCollection 2015.

32.

Gentle Nearest Neighbors Boosting over Proper Scoring Rules.

Nock R, Ali WB, D'Ambrosio R, Nielsen F, Barlaud M.

IEEE Trans Pattern Anal Mach Intell. 2015 Jan;37(1):80-93. doi: 10.1109/TPAMI.2014.2307877.

PMID:
26353210
33.

Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease.

Grancini V, Trombetta M, Lunati ME, Zimbalatti D, Boselli ML, Gatti S, Donato MF, Resi V, D'Ambrosio R, Aghemo A, Pugliese G, Bonadonna RC, Orsi E.

J Hepatol. 2015 Dec;63(6):1484-90. doi: 10.1016/j.jhep.2015.08.011. Epub 2015 Aug 20.

PMID:
26297917
34.

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy.

D'Ambrosio R, Della Corte C, Colombo M.

Int J Mol Sci. 2015 Aug 19;16(8):19698-712. doi: 10.3390/ijms160819698. Review.

35.

Temperatures achieved in human and canine neocortex during intraoperative passive or active focal cooling.

Smyth MD, Han RH, Yarbrough CK, Patterson EE, Yang XF, Miller JW, Rothman SM, D'Ambrosio R.

Ther Hypothermia Temp Manag. 2015 Jun;5(2):95-103. doi: 10.1089/ther.2014.0025. Epub 2015 Apr 22.

36.

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.

Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D'Ambrosio R, Maggioni M, De Francesco R, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L.

Hepatology. 2015 Jul;62(1):111-7. doi: 10.1002/hep.27811. Epub 2015 May 6.

PMID:
25820484
37.

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

Covelli D, Vannucchi G, Campi I, Currò N, D'Ambrosio R, Maggioni M, Gianelli U, Beck-Peccoz P, Salvi M.

J Clin Endocrinol Metab. 2015 May;100(5):1731-7. doi: 10.1210/jc.2014-4463. Epub 2015 Mar 9.

PMID:
25751109
38.

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

D'Ambrosio R, Aghemo A, Colombo M.

Expert Opin Drug Saf. 2015 Mar;14(3):473-84. doi: 10.1517/14740338.2015.1009035. Epub 2015 Feb 3. Review.

PMID:
25645644
39.

Optimized methods for epilepsy therapy development using an etiologically realistic model of focal epilepsy in the rat.

Eastman CL, Fender JS, Temkin NR, D'Ambrosio R.

Exp Neurol. 2015 Feb;264:150-62. doi: 10.1016/j.expneurol.2014.12.010. Epub 2014 Dec 16.

40.

Detection of auto-antibodies to DAT in the serum: interactions with DAT genotype and psycho-stimulant therapy for ADHD.

Giana G, Romano E, Porfirio MC, D'Ambrosio R, Giovinazzo S, Troianiello M, Barlocci E, Travaglini D, Granstrem O, Pascale E, Tarani L, Curatolo P, Laviola G, Adriani W.

J Neuroimmunol. 2015 Jan 15;278:212-22. doi: 10.1016/j.jneuroim.2014.11.008. Epub 2014 Nov 18.

PMID:
25468771
41.

Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.

Fabrizi F, D'Ambrosio R, Pallotti F, Berardinelli L, Messa P, Martin P, Aghemo A.

Int J Artif Organs. 2014 Nov;37(11):803-8. doi: 10.5301/ijao.5000359. Epub 2014 Oct 13.

PMID:
25362901
42.

Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.

De Nicola S, Dongiovanni P, Aghemo A, Cheroni C, D'Ambrosio R, Pedrazzini M, Marabita F, Donnici L, Maggioni M, Fargion S, Colombo M, De Francesco R, Valenti L.

PLoS One. 2014 Aug 29;9(8):e106022. doi: 10.1371/journal.pone.0106022. eCollection 2014.

43.

The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.

D'Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S, Cheroni C, Clark PJ, Ronchi G, Lampertico P, Colombo M.

Int J Mol Sci. 2014 Apr 25;15(5):7213-24. doi: 10.3390/ijms15057213.

44.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M.

PLoS One. 2014 Apr 23;9(4):e95881. doi: 10.1371/journal.pone.0095881. eCollection 2014.

45.

Subtypes of post-traumatic epilepsy: clinical, electrophysiological, and imaging features.

Gupta PK, Sayed N, Ding K, Agostini MA, Van Ness PC, Yablon S, Madden C, Mickey B, D'Ambrosio R, Diaz-Arrastia R.

J Neurotrauma. 2014 Aug 15;31(16):1439-43. doi: 10.1089/neu.2013.3221. Epub 2014 Jul 28.

46.

Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.

Fabrizi F, Aghemo A, Fogazzi GB, Moroni G, Passerini P, D'Ambrosio R, Messa P.

Kidney Blood Press Res. 2013;38(1):52-60. doi: 10.1159/000355753. Epub 2014 Feb 10.

47.

Numerical solution of a diffusion problem by exponentially fitted finite difference methods.

D'Ambrosio R, Paternoster B.

Springerplus. 2014 Aug 11;3:425. doi: 10.1186/2193-1801-3-425. eCollection 2014.

48.

De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Fabrizi F, Aghemo A, Moroni G, Passerini P, D'Ambrosio R, Martin P, Messa P.

Dig Dis Sci. 2014 Mar;59(3):691-5. doi: 10.1007/s10620-013-2959-4. Epub 2013 Dec 8. Review. No abstract available.

PMID:
24318802
49.

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M.

J Viral Hepat. 2013 Dec;20(12):858-66. doi: 10.1111/jvh.12113. Epub 2013 Jun 24.

PMID:
24304455
50.

Safety of direct antiviral agents in real life.

D'Ambrosio R, Colombo M.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S363-6. doi: 10.1016/j.dld.2013.07.012. Review.

PMID:
24091117

Supplemental Content

Loading ...
Support Center